Among the challenges of treating women with chronic myeloid leukemia (CML) who may want to become pregnant is the lack of clear information regarding the dose of tyrosine kinase inhibitors (TKIs) and the exposure time. “The concept of stopping therapy is a relatively new one,” revealed Ellin Berman, MD, Professor of Medicine, Memorial Sloan Kettering Cancer Center, and panel member of the NCCN Guidelines for CML. “There are not, as yet, clear guidelines for who can safely stop therapy,” she told the audience at the NCCN 23rd Annual Conference.
Dr. Berman has disclosed that she has received consulting fees/honoraria from Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Takeda Pharmaceuticals North America, Inc.
HughesTPHochhausABranford. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood2010;116:3758–3765.
CortesJESaglioGKantarjianHM. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patient trials. J Clin Oncol2016;34:2333–2340.
HochhausASaglioGHughesTP. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia2016;30:1044–1054.
CortesJMauroMSteegmannJL. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA Adverse Event Reporting System. Am J Hematol2015;90:E66–72.
MahonFXRichterJGuilhotJ. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the EURO-SKI trial [abstract]. Blood2016;128:787.
BurwickRMKuoKBrewerD. Maternal, fetal, and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy. Obstet Gynecol2017;129:831–834.
Novartis: Gleevec (imatinib mesylate) tablets for oral use. Highlights of Prescribing Information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf. Accessed March 30 2018.
Novartis: Tasigna (nilotinib) capsules. Highlights of Prescribing Information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022068lbl.pdf. Accessed March 30 2018.